Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant - PA: Musculoskeletal Health, Arthritis, Skin and Oral Health

Université Laval

$100,000.00

Validation of genetic determinants of peak bone mass and post-menopausal bone density in women using SNPs and CNVs.

EF 2009-10

Résumé
Osteoporosis is a common disease affecting a majority of old women. It is characterized by low bone mass, architectural deterioration of bone tissue and an increased risk of fractures. Bone density is affected more strongly by the genetic background of an individual than by the life habits and environment. However, few gene variants have been associated with high confidence to bone density. Recently, studies looking at the whole genome have been published in relation to bone density. These studies revealed several new putative for low bone density but these associations need to be validated in independent samples. Also, some markers might be important for peak bone mass while others might be important for the rate of bone loss observed during the menopause transition. We have collected a large number of women of different (pre and post) menopausal status to help define the role of these putative gene variants. Some of these variants may also signal the role of close-by large deletion or duplication in the genome, and we will test them directly. Validated genetic markers involved in peak bone mass could be evaluated in young women and those at risk of low peak could be counselled to adopt a lifestyle that allow reaching optimal peak bone mass. Markers involved in bone loss could later be tested to identify those who will benefit the most from antiresorptive treatment. It may thus become possible to identify individuals with a higher susceptibility to low bone density and establish, in early adulthood, focused (or even tailored) preventive programs to minimize their risk of bone fracture later in their life. Such a strategy using validated genetic markers of future low bone density may allow to diminish the burden of this disease, that will undoubtedly increase further in the future due to population ageing.
Programme
Operating Grant - PA: Musculoskeletal Health, Arthritis, Skin and Oral Health
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
208839
Name
Rousseau François
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Biological and Clinical Aspects of Aging
Projecttitle
Validation of genetic determinants of peak bone mass and post-menopausal bone density in women using SNPs and CNVs.
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - PA: Musculoskeletal Health, Arthritis, Skin and Oral Health
Keyworddelim
Bone Metabolism; Human Genetics; Laboratory Medicine; Osteoporosis; Peak Bone Mass; Translational Research
Abstract
Osteoporosis is a common disease affecting a majority of old women. It is characterized by low bone mass, architectural deterioration of bone tissue and an increased risk of fractures. Bone density is affected more strongly by the genetic background of an individual than by the life habits and environment. However, few gene variants have been associated with high confidence to bone density. Recently, studies looking at the whole genome have been published in relation to bone density. These studies revealed several new putative for low bone density but these associations need to be validated in independent samples. Also, some markers might be important for peak bone mass while others might be important for the rate of bone loss observed during the menopause transition. We have collected a large number of women of different (pre and post) menopausal status to help define the role of these putative gene variants. Some of these variants may also signal the role of close-by large deletion or duplication in the genome, and we will test them directly. Validated genetic markers involved in peak bone mass could be evaluated in young women and those at risk of low peak could be counselled to adopt a lifestyle that allow reaching optimal peak bone mass. Markers involved in bone loss could later be tested to identify those who will benefit the most from antiresorptive treatment. It may thus become possible to identify individuals with a higher susceptibility to low bone density and establish, in early adulthood, focused (or even tailored) preventive programs to minimize their risk of bone fracture later in their life. Such a strategy using validated genetic markers of future low bone density may allow to diminish the burden of this disease, that will undoubtedly increase further in the future due to population ageing.
Competitiondate
201003
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rousseau, François
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~